featured News Trending

Eli Lilly Strengthens Lead in Obesity Drug Race

By 85 0

Pharmaceutical giant Eli Lilly has reinforced its dominance in the rapidly growing obesity treatment market after presenting promising trial results for its experimental drug retatrutide. Data shared at the American Diabetes Association conference showed the once-weekly injection could deliver greater weight loss than any obesity drug currently available or under development, boosting investor confidence in the company’s future prospects.

Several competitors, including Roche, AstraZeneca, Pfizer, and Novo Nordisk, also unveiled new obesity treatment data. While their drugs showed comparable weight-loss results to existing therapies, analysts believe Lilly’s next-generation products remain ahead of the competition. Following the conference, Lilly’s shares rose while several rival drugmakers saw declines.

As more obesity treatments enter development, companies are increasingly focusing on different patient needs, balancing weight-loss effectiveness with improved tolerability. Side effects such as nausea and vomiting remain a major challenge for current GLP-1-based therapies, prompting manufacturers to invest in newer options that offer fewer gastrointestinal issues while maintaining strong results.

Pic courtesy: google/ images are subject to copyright

featured News Trending

Pfizer Prepares Sweeter Bid in Intensifying Battle for Metsera

By 348 0

Pfizer is preparing to raise its offer for obesity drugmaker Metsera after a U.S. judge refused to block rival Novo Nordisk’s $10 billion bid, according to a source. The pharmaceutical giant is scrambling to keep its takeover plans alive as its current merger agreement with Metsera is set to expire at midnight ET without an improved proposal. The fierce competition reflects the companies’ push to secure a foothold in a rapidly expanding obesity treatment market projected to reach $150 billion by the early 2030s.

The bidding war, which began privately in January, escalated into public view when Novo launched an unsolicited proposal last week—its seventh attempt—undermining Pfizer’s earlier $7.3 billion deal. Both companies raised their offers on Tuesday, with Pfizer valuing Metsera at up to $8.1 billion and Novo offering a mix of upfront cash and milestone-based payments. The uncertainty has caused Metsera’s stock to swing, falling 2.5% Wednesday before rising in after-hours trading.

Regulatory challenges are adding further complications. The U.S. Federal Trade Commission warned that Novo’s deal structure may violate antitrust rules without proper premerger review, while Pfizer’s claim that the rival offer is illegal was rejected in court. As Pfizer seeks to overcome past setbacks in the obesity space and Novo tries to regain ground lost to Eli Lilly, control of Metsera—and its next-generation GLP-1 drug pipeline—remains hotly contested.

Pic Courtesy: google/ images are subject to copyright